These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
343 related items for PubMed ID: 19601709
1. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia. Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K, ARANESP 20030232 Study Group. Curr Med Res Opin; 2009 Sep; 25(9):2109-20. PubMed ID: 19601709 [Abstract] [Full Text] [Related]
2. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P. Oncologist; 2006 Apr; 11(4):409-17. PubMed ID: 16614237 [Abstract] [Full Text] [Related]
3. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. Canon JL, Vansteenkiste J, Bodoky G, Mateos MV, Bastit L, Ferreira I, Rossi G, Amado RG. J Natl Cancer Inst; 2006 Feb 15; 98(4):273-84. PubMed ID: 16478746 [Abstract] [Full Text] [Related]
4. A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia. Kotasek D, Canon JL, Mateos MV, Hedenus M, Rossi G, Taylor K. Curr Med Res Opin; 2007 Jun 15; 23(6):1387-401. PubMed ID: 17559735 [Abstract] [Full Text] [Related]
5. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, Knusel B, Armstrong P, Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group. Circulation; 2008 Jan 29; 117(4):526-35. PubMed ID: 18195176 [Abstract] [Full Text] [Related]
6. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Auerbach M, Silberstein PT, Webb RT, Averyanova S, Ciuleanu TE, Shao J, Bridges K. Am J Hematol; 2010 Sep 29; 85(9):655-63. PubMed ID: 20661916 [Abstract] [Full Text] [Related]
7. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P. Eur Heart J; 2007 Sep 29; 28(18):2208-16. PubMed ID: 17681958 [Abstract] [Full Text] [Related]
8. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia. Charu V, Saidman B, Ben-Jacob A, Justice GR, Maniam AS, Tomita D, Rossi G, Rearden T, Glaspy J. Oncologist; 2007 Oct 29; 12(10):1253-63. PubMed ID: 17962619 [Abstract] [Full Text] [Related]
9. Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study. Gordon D, Nichols G, Ben-Jacob A, Tomita D, Lillie T, Miller C. Oncologist; 2008 Jun 29; 13(6):715-24. PubMed ID: 18586927 [Abstract] [Full Text] [Related]
10. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial. Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Hamilton L, Bridges K, Pujol B. BMC Cancer; 2009 Sep 03; 9():311. PubMed ID: 19728887 [Abstract] [Full Text] [Related]
11. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Hesketh PJ, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, Colowick A, Schwartzberg L, Bertoli LF, Cole JT, Demetri G, Dessypris E, Dobbs T, Eisenberg P, Fleischman R, Hall J, Hoffman PC, Laber DA, Leonard J, Lester EP, McCachren S, McMeekin S, Meza L, Miller DS, Nand S, Oliff I, Paroly W, Pawl L, Perez A, Raftopoulos H, Rigas J, Rowland K, Scullin DC, Tezcan H, Waples J, Ward J, Yee LK. Cancer; 2004 Feb 15; 100(4):859-68. PubMed ID: 14770445 [Abstract] [Full Text] [Related]
12. The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia. Boccia R, Lillie T, Tomita D, Balducci L. Oncologist; 2007 May 15; 12(5):584-93. PubMed ID: 17522247 [Abstract] [Full Text] [Related]
13. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. 20030125 Study Group TrialUniversity of California Los Angeles School of Medicine, Los Angeles, CA 90095, USA. jglaspy@mednet.ucla.edu, Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV, Tomita D, Rossi G. J Clin Oncol; 2006 May 20; 24(15):2290-7. PubMed ID: 16710026 [Abstract] [Full Text] [Related]
14. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR). Hertel J, Locay H, Scarlata D, Jackson L, Prathikanti R, Audhya P. Am J Nephrol; 2006 May 20; 26(2):149-56. PubMed ID: 16636531 [Abstract] [Full Text] [Related]
15. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT). Martelli O, Garassino M, Sacchetta S, Caristo R, Zivi A, Cerbone L, Mancuso A. Anticancer Res; 2008 May 20; 28(3B):1767-71. PubMed ID: 18630457 [Abstract] [Full Text] [Related]
16. Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial. Schwartzberg L, Burkes R, Mirtsching B, Rearden T, Silberstein P, Yee L, Inamoto A, Lillie T. BMC Cancer; 2010 Oct 25; 10():581. PubMed ID: 20973982 [Abstract] [Full Text] [Related]
17. RETRA: evaluating the transfusion rate with darbepoetin alfa 500 µg every 3 weeks in anaemic cancer patients receiving chemotherapy. Eisterer W, Hussl C, Erb H, Haslbauer F, Sormann S, Braun S, Jaeger C. Curr Med Res Opin; 2011 Feb 25; 27(2):355-63. PubMed ID: 21166611 [Abstract] [Full Text] [Related]
18. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial. Charu V, Belani CP, Gill AN, Bhatt M, Tomita D, Rossi G, Ben-Jacob A. Oncologist; 2007 Jun 25; 12(6):727-37. PubMed ID: 17602062 [Abstract] [Full Text] [Related]
19. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ. Am J Kidney Dis; 2002 Jul 25; 40(1):110-8. PubMed ID: 12087568 [Abstract] [Full Text] [Related]
20. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. Ponikowski P, Anker SD, Szachniewicz J, Okonko D, Ledwidge M, Zymlinski R, Ryan E, Wasserman SM, Baker N, Rosser D, Rosen SD, Poole-Wilson PA, Banasiak W, Coats AJ, McDonald K. J Am Coll Cardiol; 2007 Feb 20; 49(7):753-62. PubMed ID: 17306703 [Abstract] [Full Text] [Related] Page: [Next] [New Search]